A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

← catalyst calendar

NCT05395481

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 1

Status

Completed

Study type

Interventional

Design

Randomized · Double · Basic science

Enrollment

115actual

Sites

Countries

Japan, Puerto Rico, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-06-08

actual

When the study began enrolling

Primary completion

2026-05-12

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-05-12

actual

The whole study's end, after follow-up

First posted

2022-05-27

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-24

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

Interventions

Drug: LY3849891
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration

measured Predose up to 26 weeks post dose

Part B: Pharmacodynamics (PD): Mean change from baseline on liver inflammation and fibrosis measured by magnetic resonance imaging (MRI)

measured Baseline through 24 weeks

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed